Solid performance for the quarter and the first half of the year despite the effects of the pandemic
Second quarter 2020
January-June 2020
“Despite extremely difficult market conditions due to the Covid-19 pandemic, Mentice’s
performance during the second quarter has been solid, resulting in a strong first half-year
financial result. For the first half of the year, orders received were 1,6 % above the first half of
2019, while net sales were 2.9 % lower compared to the first six months of 2019,” says Göran Malmberg, CEO of Mentice AB (publ).
Webcast presentation of the interim report
Mentice's interim report for January–June 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on August 13, 2020 at 09:30 CET. The presentation will be held via the web and in English.
To register for the presentation, please visit www.mentice.com/financial-reports-presentations.
Please make sure to register at least a few minutes in advance.
For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: goran.malmberg@mentice.com
Tel US: +1 (312) 860 5610
Tel Sweden: +46 (0) 703 09 22 22
This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on August 13, 2020 08:30 CEST.
Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se
>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.
Subscribe to automatically receive our press releases in your mailbox.
Solid performance for the quarter and the first half of the year despite the effects of the pandemic
Second quarter 2020
January-June 2020
“Despite extremely difficult market conditions due to the Covid-19 pandemic, Mentice’s
performance during the second quarter has been solid, resulting in a strong first half-year
financial result. For the first half of the year, orders received were 1,6 % above the first half of
2019, while net sales were 2.9 % lower compared to the first six months of 2019,” says Göran Malmberg, CEO of Mentice AB (publ).
Webcast presentation of the interim report
Mentice's interim report for January–June 2020 will be presented by CEO Göran Malmberg with the possibility to ask questions on August 13, 2020 at 09:30 CET. The presentation will be held via the web and in English.
To register for the presentation, please visit www.mentice.com/financial-reports-presentations.
Please make sure to register at least a few minutes in advance.
For further information, please contact:
Göran Malmberg, CEO, Mentice
Email: goran.malmberg@mentice.com
Tel US: +1 (312) 860 5610
Tel Sweden: +46 (0) 703 09 22 22
This information is information that Mentice AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person on August 13, 2020 08:30 CEST.
Market place: Nasdaq First North Premier, Stockholm | Ticker symbol: MNTC
Certified Adviser: FNCA Sweden AB, tel +46 8 528 00 399 e-post info@fnca.se
>20 years of innovation in medical simulation | more information at www.mentice.com
Mentice is the world leader in software and hardware simulation solutions for endovascular therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular and peripheral interventions are just some of the clinical areas covered by our solutions.
Prenumerera för att automatiskt få våra pressmeddelanden i din brevlåda.